The effect of trichloromethiazide in autosomal dominant polycystic kidney disease patients using tolvaptan: randomized crossover controlled trial
Not Applicable
- Conditions
- Autosomal dominant polycystic kidney disease
- Registration Number
- JPRN-UMIN000037550
- Lead Sponsor
- Division of Nephrology, Japanese Red Cross Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria are as follows: patients with uncontrolled persistent hypertension (systolic blood pressure >= 180 mmHg or diastolic pressure >= 110 mmHg); Hyponatremia (serum Na < 135 mEq/L) and/or hypokalemia (serum K < 3.5 mEq/L); prior symptomatic coronary artery or cerebrovascular diseases within the previous 3 months; uncontrolled heart failure (NYHA >= III); symptomatic or lethal arrhythmia; severe valvular diseases.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method